Tocqueville Asset Management’s Immix Biopharma IMMX Stock Holding History

Tocqueville Asset Management’s Portfolio IMMX Stock Details IMMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$913K	Sell	88,550 -1,000	-1%	-$9.28K	0.01%	381
2026 Q1	$816K	Buy	89,550 +21,000	+31%	+$154K	0.01%	384
2025 Q4	$359K	Buy	68,550 +28,300	+70%	+$116K	0.01%	492
2025 Q3	$84.1K	Buy	40,250 +10,950	+37%	+$26.3K	﹤0.01%	545
2025 Q2	$60.7K	Hold	29,300	–	–	﹤0.01%	533
2025 Q1	$49.2K	Sell	29,300 -9,000	-23%	-$17K	﹤0.01%	510
2024 Q4	$84.3K	Sell	38,300 -5,000	-12%	-$9.13K	﹤0.01%	534
2024 Q3	$64.5K	Buy	43,300 +5,500	+15%	+$11.1K	﹤0.01%	521
2024 Q2	$74.8K	Hold	37,800	–	–	﹤0.01%	518
2024 Q1	$116K	Buy	37,800 +17,800	+89%	+$68.9K	﹤0.01%	523
2023 Q4	$138K	Buy	20,000 +8,000	+67%	+$36.2K	﹤0.01%	501
2023 Q3	$41K	Buy	+12,000	New	+$28.1K	﹤0.01%	506

Other funds holding IMMX

Jupiter Topco New York $245B AUM

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Tocqueville Asset Management's IMMX Position: Q2 2026 in Review

Tocqueville Asset Management reduced its Immix Biopharma (IMMX) stake by 1.1% in Q2 2026, selling an estimated $9.28K and leaving 88,550 shares worth $913K. The position accounts for 0.01% of the portfolio, ranked #381.

Tocqueville Asset Management first reported a position in IMMX in Q3 2023 and has held it in 12 quarters since. 109 funds tracked by Wall St. Rank hold IMMX as of Q2 2026.

Tocqueville Asset Management held 88,550 shares of Immix Biopharma worth $913K as of Q2 2026.
Tocqueville Asset Management sold 1,000 Immix Biopharma shares in Q2 2026, an estimated $9.28K.
Immix Biopharma made up 0.01% of Tocqueville Asset Management's portfolio in Q2 2026, its #381 holding.
Tocqueville Asset Management first reported a position in Immix Biopharma in Q3 2023 and has held it in 12 quarters since.
109 funds tracked by Wall St. Rank held Immix Biopharma as of Q2 2026.

Based on Tocqueville Asset Management's 13F filing for Q2 2026, filed 10 Aug 2026.